Bayer AG filed the lawsuit in US District Court in the Southern District of New York, claiming that Watson Pharmaceuticals Inc. and Novartis AG's infringed on its patent by seeking approval in the US to market generic versions of Yasmin, according to Reuters.
The case is officially known as Bayer Schera Pharma AG and Bayer Healthcare Pharmaceuticals Inc. v. Sandoz Inc., Watson Pharmaceuticals Inc. and Watson Laboratories Inc. The judge in the case said that Bayer's patent does not claim a use that has met the approval of the US Food and Drug Administration.
The judge dismissed Bayer's case "with prejudice," which means that the company can not bring the patent infringement lawsuit to court again.
The use of Yasmin oral contraceptives have been linked to a number of serious side effects that include an increased risk of the development of blood clots and stroke.